Cover Image
市場調查報告書

Zyngenia, Inc.:產品平台分析

Zyngenia, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 308423
出版日期 內容資訊 英文 24 Pages
訂單完成後即時交付
價格
Back to Top
Zyngenia, Inc.:產品平台分析 Zyngenia, Inc. - Product Pipeline Review - 2015
出版日期: 2015年05月27日 內容資訊: 英文 24 Pages
簡介

Zyngenia, Inc.是開發癌症,發炎性疾病,自體免疫疾病治療藥的生物醫藥品公司。正在開發應用Zybody技術的單株抗體之治療藥。

本報告提供Zyngenia, Inc.之調查分析,提供您治療藥的開發平台最新資訊,加上各開發階段比較分析,藥物標的·作用機制·給藥途徑·各分子類型的治療藥評估,也包含最新消息和新聞稿,後期階段·中止的計劃等系統性資訊。

目錄

Zyngenia, Inc.的基本資料

  • Zyngenia, Inc.概要
  • 主要資訊
  • 企業資料

Zyngenia, Inc.:研究開發概要

  • 主要的治療領域

Zyngenia, Inc.:開發平台檢驗

  • 開發中產品:各開發階段
  • 開發中產品:單獨療法
  • 開發中產品:合作夥伴產品

Zyngenia, Inc.:開發中產品的概要

  • 初期階段的開發中產品

Zyngenia, Inc.:藥物簡介

  • Monoclonal Antibodies for Cancer, Inflammation and Autoimmune Diseases
  • Monoclonal Antibody to Agonize TRAIL Receptor 2 for Multiple Myeloma
  • Monoclonal Antibody to Antagonize HER-1 and HER-3 for Cancer
  • Monoclonal Antibody to Inhibit Ang-2 and TNF-a for Ulcerative Colitis, Arthritis and Inflammatory Disease
  • Monoclonal Antibody Conjugate to Antagonize HER-2 for Metastatic Breast Cancer

Zyngenia, Inc.:開發平台分析

  • 開發中產品:標的別
  • 開發中產品:各分子類型
  • 開發中產品:各作用機制

Zyngenia, Inc.:開發平台的最新趨勢

Zyngenia, Inc.:所在地與子公司

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07119CDB

Summary

Global Markets Direct's, 'Zyngenia, Inc. - Product Pipeline Review - 2015', provides an overview of the Zyngenia, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Zyngenia, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Zyngenia, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Zyngenia, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Zyngenia, Inc.'s pipeline products

Reasons to buy

  • Evaluate Zyngenia, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Zyngenia, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Zyngenia, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Zyngenia, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Zyngenia, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Zyngenia, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Zyngenia, Inc. Snapshot
    • Zyngenia, Inc. Overview
    • Key Information
    • Key Facts
  • Zyngenia, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Zyngenia, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Zyngenia, Inc. - Pipeline Products Glance
    • Zyngenia, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Zyngenia, Inc. - Drug Profiles
    • Monoclonal Antibodies for Cancer, Inflammation and Autoimmune Diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Agonize TRAIL Receptor 2 for Multiple Myeloma
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Antagonize HER-1 and HER-3 for Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit Ang-2 and TNF-a for Ulcerative Colitis, Arthritis and Inflammatory Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody Conjugate to Antagonize HER-2 for Metastatic Breast Cancer
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Zyngenia, Inc. - Pipeline Analysis
    • Zyngenia, Inc. - Pipeline Products by Target
    • Zyngenia, Inc. - Pipeline Products by Molecule Type
    • Zyngenia, Inc. - Pipeline Products by Mechanism of Action
  • Zyngenia, Inc. - Recent Pipeline Updates
  • Zyngenia, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Zyngenia, Inc., Key Information
  • Zyngenia, Inc., Key Facts
  • Zyngenia, Inc. - Pipeline by Indication, 2015
  • Zyngenia, Inc. - Pipeline by Stage of Development, 2015
  • Zyngenia, Inc. - Monotherapy Products in Pipeline, 2015
  • Zyngenia, Inc. - Partnered Products in Pipeline, 2015
  • Zyngenia, Inc. - Partnered Products/ Combination Treatment Modalities, 2015
  • Zyngenia, Inc. - Preclinical, 2015
  • Zyngenia, Inc. - Discovery, 2015
  • Zyngenia, Inc. - Pipeline by Target, 2015
  • Zyngenia, Inc. - Pipeline by Molecule Type, 2015
  • Zyngenia, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Zyngenia, Inc. - Recent Pipeline Updates, 2015

List of Figures

  • Zyngenia, Inc. - Pipeline by Top 10 Indication, 2015
  • Zyngenia, Inc. - Pipeline by Stage of Development, 2015
  • Zyngenia, Inc. - Monotherapy Products in Pipeline, 2015
  • Zyngenia, Inc. - Pipeline by Top 10 Target, 2015
  • Zyngenia, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Zyngenia, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top